Plain-English translation of NCT04858412 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing HMB-enriched amino acid supplement (HMB/EAA)—a nutritional product designed to help rebuild muscle—in people with both COVID-19 pneumonia and alcoholic liver disease. Researchers believe this medication may help prevent serious breathing complications and speed recovery by strengthening muscles and boosting immune function. The study will compare this new treatment to a standard amino acid supplement over 90 days.
Patients with both COVID-19 and liver disease are at very high risk of severe illness and rapid decline. This medication has shown promise in rebuilding muscle strength and improving immune function, which could help prevent life-threatening breathing failure and improve long-term recovery in this vulnerable group.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to receive either the new amino acid supplement or a standard amino acid supplement by mouth for 90 days. You'll visit the clinic for check-ups, blood work, and possibly a muscle biopsy (a small tissue sample taken from your muscle). The study team will monitor your breathing, muscle strength, and recovery throughout the 90-day period and beyond.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States